Philippe Pierre Goupit
Chairman chez Tollys
Profil
Philippe Pierre Goupit is currently the Chairman at Tollys and also holds a Chairman position at Burgin & Co. He previously worked as a Director at Fovea Pharmaceuticals SA from 2010 to 2013, and as a Director at MedDay Pharmaceuticals SAS from 2014 to 2021.
He also served as an Independent Non-Executive Director at Lysogene SA and as an Independent Director at Inventiva SA from 2015 to 2017.
Prior to that, he worked at Sanofi for 20 years, where he held the position of Vice President-Mergers & Acquisitions.
Goupit obtained his undergraduate degree from Université de Paris 5 René Descartes.
Postes actifs de Philippe Pierre Goupit
Sociétés | Poste | Début |
---|---|---|
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | Chairman | 01/04/2020 |
Burgin & Co. | Chairman | - |
Anciens postes connus de Philippe Pierre Goupit
Sociétés | Poste | Fin |
---|---|---|
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Director/Board Member | 01/01/2021 |
INVENTIVA | Director/Board Member | 30/05/2017 |
SANOFI | Investor Relations Contact | 01/12/2014 |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Director/Board Member | 01/01/2013 |
LYSOGENE | Director/Board Member | - |
Formation de Philippe Pierre Goupit
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
SANOFI | Health Technology |
LYSOGENE | Commercial Services |
INVENTIVA | Health Technology |
Entreprise privées | 5 |
---|---|
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
Université de Paris 5 René Descartes | Consumer Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
Tollys
Tollys Hospital/Nursing ManagementHealth Services Tollys is a French company that specializes in developing clinical-grade TLR3 ligands for cancer immunotherapy. The company is based in Lyon, France and was founded by Dominique Rigal. The company's co-founders discovered that TLR3 agonists have the potential to induce direct and immunogenic tumor cell death while sparing normal cells. Tollys has filled a patent for a new family of TLR3 ligands and confirmed freedom to operate. The CEO is Vincent Charlon. | Health Services |
Burgin & Co. |